The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

Table 7

Estimated overall survival and failure-free survival probabilities at time points of interest along with corresponding 95% CIs (𝑛=23).

At Time (months)	OS Probability	95% CI	FFS Probability	95% CI
6	0.96	0.73–0.99	0.78	0.55–0.90
12	0.61	0.38–0.77	0.52	0.31–0.70
24	0.57	0.34–0.74	0.48	0.27–0.66
36	0.48	0.27–0.66	0.43	0.23–0.62